RACC stock forecast, quote, news & analysis
Research Alliance Corporation III is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses... Show more
Research Alliance Corporation III (RACC) Stock Analysis: A New Healthcare SPAC Trading Near Its Trust Value
Key Takeaways
- Research Alliance Corporation III (RACC) is a special purpose acquisition company (SPAC) sponsored by RA Capital, targeting a business combination in healthcare and life sciences.
- The company priced a $75 million initial public offering in May 2026, listing 7.5 million Class A shares at $10.00 per share on the Nasdaq Capital Market.
- Shares closed near $10.12 in late October 2026, down roughly 6.8% from the late-September close of $10.86, a modest pullback within a narrow trading range.
- As a blank-check vehicle, RACC's price action remains anchored to its roughly $10.00 per-share trust value rather than operating fundamentals.
- Investors follow RACC primarily for its pending business combination target, sponsor reputation, and SPAC redemption dynamics rather than current earnings.
- For more detail on valuation and expectations, explore RACC's Price Targets, Earnings, and Forecast pages.
- Discover top-performing automated strategies in Tickeron's Trending AI Robots.
Current Market Snapshot
RACC has exhibited the low-volatility, range-bound trading typical of a pre-deal SPAC. After debuting at $10.00 per share in May 2026, the stock has generally hovered near its trust value, with intraday moves concentrated in a band between roughly $9.60 and $11.15 across the available trading period. In late October 2026, shares traded around $10.12, reflecting a decline of about 6.8% from the $10.86 close recorded in late September. Trading volume has remained relatively thin, consistent with a security whose near-term valuation is driven by cash held in trust and deal progress rather than quarterly earnings or revenue.
Research Alliance Corporation III (RACC) Business Overview and Competitive Position
Research Alliance Corporation III is a Cayman Islands-incorporated, New York-based special purpose acquisition company formed to identify and complete a merger, share exchange, asset acquisition, or similar transaction with one or more operating businesses. The company is sponsored by RA Capital, a healthcare and life sciences investment platform, which signals a likely focus on biotechnology, medical technology, and related sectors for its eventual combination target. As a blank-check company, RACC generates no operating revenue; its value proposition to investors is the expertise of its sponsor and management team, led by CEO Matthew Hammond, and the potential upside of a completed business combination. The IPO raised $75 million, and the proceeds are held in a trust account pending a qualifying transaction.
Recent Developments Driving RACC
RACC's most significant event to date remains its May 2026 IPO, in which 7.5 million Class A ordinary shares were priced at $10.00, with an additional over-allotment option available to underwriters. Since listing, the company has progressed toward its stated objective of completing a business combination, with SEC communications referencing a potential combination involving RA Capital Healthcare. In the absence of a definitive target announcement, the stock has drifted modestly lower over the trailing 30 days, moving from about $10.86 to roughly $10.12, as investors weigh the still-unresolved question of which asset the sponsor will ultimately bring public. The limited float and intermittent trading volumes have contributed to the stock's quiet, near-trust-value price action.
Trending AI Robots
Tickeron's Trending AI Robots page showcases a curated selection of automated trading bots drawn from a platform of hundreds of AI-driven strategies that monitor thousands of tickers. Only the top-performing and most relevant bots appear in this section, giving traders a focused view of strategies that are currently standing out. The bots vary in approach, timeframe, and performance metrics, ranging from short-term momentum models to longer-horizon trend-following systems, allowing users to evaluate strategies that fit different risk profiles. For investors seeking systematic, data-driven perspectives across the market, exploring the Trending AI Robots page can be a useful starting point.
2026 Outlook and What Investors Should Watch
Looking ahead, the primary catalyst for RACC is the announcement and completion of its initial business combination. Investors should monitor whether the company identifies a definitive target, the terms of any proposed deal, and how the sponsor's healthcare focus shapes the eventual asset. Key risk factors include the possibility of shareholder redemptions, an extension of the company's deadline to complete a transaction, and the general market environment for newly public healthcare companies. As with all SPACs, the gap between the share price and the cash held in trust is a central consideration, since the trust value effectively establishes a floor for shares in many scenarios. The company's governing documents provide a 24-month window from the offering's closing to complete a business combination, making deal progress the central variable for investors to track through 2026 and beyond.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
RACC's Stochastic Oscillator is remaining in oversold zone for 10 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where RACC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 41 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.244) is normal, around the industry mean (-542.354). P/E Ratio (0.000) is within average values for comparable stocks, (117.496). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (15.932). Dividend Yield (0.000) settles around the average of (0.020) among similar stocks. RACC's P/S Ratio (0.000) is very low in comparison to the industry average of (3.158).
The Tickeron Price Growth Rating for this company is 72 (best 1 - 100 worst), indicating slightly worse than average price growth. RACC’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. RACC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
Industry FinancialConglomerates